Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Lymphoma, Follicular, Lymphoma, Small Lymphocytic
Interventions
autologous human tumor-derived HSPPC-96
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1Phase 2 Interventional Results available

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

NCT03104699
Conditions
Advanced Cancer, Cervical Cancer
Interventions
AGEN2034
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
12
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more
Conditions
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
Botensilimab, Balstilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
17
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more
Conditions
Renal Cell Carcinoma
Interventions
HSPPC-96
Biological
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Albany, New York • Houston, Texas
Conditions
Malignant Melanoma
Interventions
HSPPC-96 or Oncophage
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 32 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
Ivermectin, Balstilmab, Pembrolizumab
Drug
Lead sponsor
Yuan Yuan
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Early Rectal Cancer, Stage I Rectal Cancer, Microsatellite Stable Rectal Carcinoma
Interventions
Botensilimab, Balstilimab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Renal Cell Carcinoma
Interventions
autologous human tumor-derived HSPPC-96
Biological
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Conditions
Pancreatic Cancer
Interventions
AGEN2373, Balstilimab, Cyclophosphamide, GVAX, AGEN2373 (RP2D), mKRASvax
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
Botensilimab, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
36
States / cities
Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 28 more
Conditions
Advanced Melanoma
Interventions
Botensilimab, Balstilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Scottsdale, Arizona • Fullerton, California • Santa Monica, California + 4 more
Conditions
Melanoma
Interventions
ipilimumab, HSPPC-96
Drug
Lead sponsor
Rabih Said
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain and Central Nervous System Tumors
Interventions
HSPPC-96, Temozolomide, Standard Surgical Resection
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more
Conditions
Advanced Cancer, Metastatic Cervical Cancer
Interventions
Balstilimab (BAL), Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Colorectal Cancer Metastatic, Liver Metastases, Colorectal Cancer
Interventions
Botensilimab, Balstilimab, AGEN1423, Radiation
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Kidney Cancer, Renal Cell Carcinoma
Interventions
HSPPC-96
Biological
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
San Francisco, California • Stanford, California • Hackensack, New Jersey + 2 more
Conditions
Advanced Solid Tumor
Interventions
AGEN1223, AGEN1223 and balstilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Miami, Florida + 1 more
Conditions
Colorectal Cancer
Interventions
Botensilimab, Balstilimab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab, Panitumumab
Drug
Lead sponsor
Nicholas DeVito, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Colorectal Cancer, Rectal Cancer
Interventions
Botensilimab, Balstilimab, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Active, not recruiting Phase 2 Interventional Results available

Combination Immunotherapy in Colorectal Cancer

NCT05571293
Conditions
Colorectal Neoplasms
Interventions
Botensilimab, Balstilimab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Brooklyn, New York • Flushing, New York • New York, New York
Conditions
Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Interventions
AGEN1423, Botensilimab, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Bruno Bockorny
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
Interventions
Stereotactic Body Radiation Therapy, Botensilimab, Balstilimab
Radiation · Drug
Lead sponsor
Benjamin Spieler
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Conditions
Advanced Cancer
Interventions
AGEN2373, Botensilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Coral Gables, Florida + 9 more
Conditions
Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis
Interventions
Stereotactic Body Radiation Therapy (SBRT), Botensilimab, Balstilimab
Radiation · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts